Loading clinical trials...
Loading clinical trials...
A Phase II Study of SPH4336 in Combination With Endocrine Therapy in HR-positive, HER2-negative Breast Cancer Patients With Brain Metastases.
Conditions
Interventions
SPH4336 Tablets
Locations
25
China
Anhui provincial hospital
Hefei, Anhui, China
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Affiliated Cancer Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Liuzhou people's Hospital
Liuchow, Guangxi, China
Anyang Cancer Hospital
Anyang, He'nan, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, He'nan, China
Start Date
September 19, 2023
Primary Completion Date
December 31, 2025
Completion Date
December 31, 2025
Last Updated
August 17, 2025
Lead Sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions